Phase 2b efficacy study with CoviLiv a proprietary live attenuated virus COVID-19 vaccine
Award Notice Posted
Not the latest version. See the latest special notice from .
- Solicitation number
- BARDABAA-18-100-SOL-00003
- Agency
-
Office of the Assistant Secretary for Preparedness and Response
Department of Health and Human Services
- Awarded
- to Codagenix Inc.
- Set-aside
- No set-aside
Opportunity facts
- Contract number
- 75A50123C00048 Federal contract award
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Place of performance
- Farmingdale, New York 11735, United States
Notice details come from SAM.gov. Updated .
About this opportunity
This competitively awarded hybrid cost-share CPFF contract valued at $389,449,172 from the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response will fund CODAGENIX INC to conduct a Phase 2b efficacy study of their proprietary live attenuated virus COVID-19 vaccine, CoviLiv. The contract awarded on September 27, 2023 provides $389,449,172 in government cost-share funding to CODAGENIX INC for the Phase 2b study of the CoviLiv vaccine.
Notice text
This is a competitively awarded hybrid cost-share CPFF contract for a Phase 2b efficacy study with CoviLiv a proprietary live attenuated virus COVID-19 vaccine. The government's cost-share amount is $389,449,172.
Awarded contract 75A50123C00048 to CODAGENIX INC for 389449172.00 on 2023-09-27.
Notice history
7 notices listed here. See the rest on GovTribe.
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity